Mortensen J, Hansen A, Falk M, Nielsen I K, Groth S
Department of Clinical Physiology, Rigshospitalet, State University Hospital, Copenhagen, Denmark.
Chest. 1993 Mar;103(3):805-11. doi: 10.1378/chest.103.3.805.
It has been suggested that the defective cyclic AMP-dependent Cl- secretion and the increased Na+ absorption from airway epithelia in cystic fibrosis (CF) may lead to dehydrated secretions and impaired mucociliary clearance. Beta 2-adrenergic agonists are unable to stimulate the Cl- transport in the airways in CF while being able to do so in normal airways. Thus, we questioned whether the beta 2-adrenergic agonist, terbutaline, would improve mucociliary clearance in patients with CF as it does in healthy subjects.
A double-blind, randomized cross-over trial.
Whole lung and regional mucociliary clearance of a radioaerosol was measured for 3 h by gamma camera. One minute of cough clearance was measured at 3 h. Pulmonary function was measured before and after the gamma camera study.
Ten young patients with CF were studied; three were heterozygous for deletion of the phenylalanine at position 508 (delta F508), and seven were delta F508 homozygous.
Inhalation of 1 mg of terbutaline (4 puffs) and placebo via a metered-dose inhaler by spacer.
The largest differences in tracheobronchial retention (percent) in the whole lung and regional lung zones were generally observed within 1 h after terbutaline and placebo treatment: whole lung (mean +/- SD), 60 +/- 22 percent and 63 +/- 20 percent; central zone, 41 +/- 19 percent and 50 +/- 25 percent; midzones, 65 +/- 27 percent and 63 +/- 19 percent; and peripheral zones, 77 +/- 28 percent and 72 +/- 28 percent, respectively [p > 0.1]. Whereas none of these differences was statistically significant, subanalyses suggested an improvement in mucociliary clearance by terbutaline in the three delta F508 heterozygous patients but not in the seven delta F508 homozygous patients. One minute of voluntary coughing resulted in clearance of less than 8 percent of the initial radioactivity, with a trend of more peripheral zone clearance after terbutaline compared with placebo. A small significant decrease in airway resistance was detected 3 h after terbutaline.
We conclude that 1 mg of terbutaline did not improve mucociliary clearance significantly in the patients with CF. Also, the effect of terbutaline was much less than demonstrated earlier in healthy subjects. This is consistent with earlier findings of a lack of beta-adrenergic modulation of Cl- transport in CF. Thus, no rehydration of the dry mucus in CF is expected, and a possible beta 2-agonist-induced increase in ciliary beating would have only a minor effect on overall mucociliary clearance.
有人提出,囊性纤维化(CF)患者气道上皮细胞中依赖环磷酸腺苷(cAMP)的氯离子分泌缺陷以及钠离子吸收增加,可能导致分泌物脱水和黏液纤毛清除功能受损。β2肾上腺素能激动剂在CF患者气道中无法刺激氯离子转运,而在正常气道中则可以。因此,我们质疑β2肾上腺素能激动剂特布他林是否能像在健康受试者中那样改善CF患者的黏液纤毛清除功能。
一项双盲、随机交叉试验。
通过γ相机测量放射性气溶胶在全肺和局部区域的黏液纤毛清除功能3小时。在3小时时测量1分钟的咳嗽清除功能。在γ相机研究前后测量肺功能。
研究了10名年轻的CF患者;3名是苯丙氨酸508位缺失(ΔF508)的杂合子,7名是ΔF508纯合子。
通过带储雾罐的定量吸入器吸入1毫克特布他林(4喷)和安慰剂。
在特布他林和安慰剂治疗后1小时内,通常观察到全肺和局部肺区域气管支气管滞留(百分比)的最大差异:全肺(均值±标准差),分别为60±22%和63±20%;中央区域,分别为41±19%和50±25%;中间区域,分别为65±27%和63±19%;外周区域,分别为77±28%和72±28%[p>0.1]。尽管这些差异均无统计学意义,但亚组分析表明,特布他林可改善3名ΔF508杂合子患者的黏液纤毛清除功能,但对7名ΔF508纯合子患者无效。1分钟的自主咳嗽导致初始放射性清除率低于8%,与安慰剂相比,特布他林治疗后外周区域清除率有增加趋势。特布他林治疗3小时后,气道阻力有小幅显著下降。
我们得出结论,1毫克特布他林在CF患者中并未显著改善黏液纤毛清除功能。此外,特布他林的效果远低于早期在健康受试者中所显示的效果。这与早期关于CF患者氯离子转运缺乏β肾上腺素能调节的研究结果一致。因此,预计CF患者干燥黏液不会得到水化,β2激动剂可能引起的纤毛摆动增加对整体黏液纤毛清除功能的影响也很小。